A once-daily pill form of the Wegovy weight loss medication, which contains the active ingredient semaglutide, is now available for private purchase in United Kingdom pharmacies. The drug makers, Novo Nordisk, also produce a jab form of Wegovy.
The medication works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which is released by the intestine after eating. Semaglutide acts on appetite-regulating receptors in the brain, promoting feelings of fullness, reducing hunger, and decreasing food cravings.
Common side effects associated with both the pill and the injection include gastrointestinal issues such as nausea, vomiting, constipation, and diarrhea. Some individuals may also experience headaches and tiredness. Those using the injectable form might notice mild redness, itching, or swelling at the injection site.
More serious, though less common, complications can arise, including low blood sugar, pancreatitis, and severe allergic reactions. Patients are advised to consult the patient information leaflet for a comprehensive list of potential side effects and risks.
Use of the medication is not recommended for individuals under 18 years of age, or for those who are pregnant or breastfeeding. It is essential for patients to discuss any pre-existing medical conditions or current medications with their doctor before starting treatment.